Nerviano Medical Sciences Receives Approval From The Fda To Enter Phase I Clinical Trials For Their

< BACK TO HEALTH starstarstarstarstar   Community - Health Press Release
13th May 2009, 11:18am - Views: 392





Community Health Nerviano Medical Sciences 1 image




Nerviano Medical Sciences Receives Approval From the FDA to Enter Phase I Clinical Trials for Their Polo

Like Kinase (PLK) Inhibitor


NERVIANO, May 13 /PRNewswire-AsiaNet/ --


    The FDA has approved an Investigational New Drug (IND)

application by Nerviano Medical Sciences to begin a phase I clinical study

with its selective PLK-1 small molecule inhibitor for the treatment of

cancer. PLK-1 is a mitotic kinase required for the proliferation of cancer

cells. This new compound is orally bioavailable, highly efficient and well

tolerated in preclinical models of cancer after repeated dosing. This unique

inhibitor adds another promising candidate to the pipeline of innovative cell

cycle targets with different mechanisms of action in clinical development

which have been discovered and developed by NMS. These include inhibitors of

CDK, Aurora and CDC-7. An IND for an inhibitor of CDC-7 was approved by the

FDA in January this year and the first patients were treated with the

compound in April. NMS CDK and Aurora inhibitors are in phase I and II

clinical development, respectively, and are starting to show promising

activity in specific patient populations.


    The clinical development path foresees application of the NMS PLK-1

inhibitor in solid and hematological indications. "I am pleased to see the

second IND approval this year and I highly appreciate the consistant delivery

of high quality clinical candidates by the Nerviano site" comments Dr.

Francesco Colotta, VP R&D at NMS.


    Nerviano Medical Sciences (NMS)


    Nerviano Medical Sciences is the largest pharmaceutical R&D

facility in Italy and one of the largest oncology-focused, integrated

discovery and development companies in Europe. Research activities in

Nerviano generate on average two clinical candidate molecules per year. NMS

takes advantage of strategic alliances with biotechnology as well as

pharmaceutical companies to secure its long term business sustainability. The

Company has already finalized partnerships with major companies such as

Pfizer Inc., Bristol-Myers Squibb Co., Genentech Inc. as well as with several

biotech companies and academic institutions.

    

    For information:


    Nerviano Medical Sciences

    Maria D'Acquino,

    tel +39-0331-581013,

    mob. +39-335-1863051,

    maria.dacquino@nervianoms.com


    SOURCE: Nerviano Medical Sciences




Translations:



To view this and other AsiaNet releases please visit http://www.asianetnews.net






news articles logo NEWS ARTICLES
Contact News Articles |Remove this article